People's Republic of; Jer-Tsong Hsieh, Dallas, TX INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy, however, the molecular events involved in RCC pathogenesis and progression are still not well defined. DAB2IP, a novel member of Ras GTPase-activating protein gene family, is associated with cell proliferation, apoptosis, metastasis and chemo-or radio-resistance in several cancers. We have recently reported the tumor suppressive role of DAB2IP in RCC development, and identified one CpG methylation biomarker located at upstream of the transcription start site of DAB2IP that was associated with poor survival in three independent large-scale cohorts of RCC patients. In the present study, we determined molecular mechanisms of DAB2IP in suppressing the growth of RCC.
INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy, however, the molecular events involved in RCC pathogenesis and progression are still not well defined. DAB2IP, a novel member of Ras GTPase-activating protein gene family, is associated with cell proliferation, apoptosis, metastasis and chemo-or radio-resistance in several cancers. We have recently reported the tumor suppressive role of DAB2IP in RCC development, and identified one CpG methylation biomarker located at upstream of the transcription start site of DAB2IP that was associated with poor survival in three independent large-scale cohorts of RCC patients. In the present study, we determined molecular mechanisms of DAB2IP in suppressing the growth of RCC.
METHODS: DAB2IP knockdown (KD) and overexpressing cells were generated by RNAi or cDNA transfection technologies. MTT, cellcycle assays and xenograft models were performed to investigate the effect of DAB2IP on RCC cell growth. Mechanisms of DAB2IP in regulating cell growth were delineated by a variety of molecular biologic techniques such as real-time PCR, western blot, and immunoprecipitation. Relationships between DAB2IP, its downstream gene and tumor size were validated by clinical samples, and the associations of critical proteins and RCC patient survival were analyzed.
RESULTS: DAB2IP KD cells exhibited promoted G1/S phase cell-cycle progression and enhanced cell proliferation, whereas, DAB2IP-overexpressing cells showed decreased growth ability. Mechanistically, DAB2IP promoted ubiquitination and degradation of a critical negative regulator of the cell-cycle, p27 (Kip1). Further signaling cascade profiling demonstrated that the Proline-rich domain in C terminal (CPR) of DAB2IP inhibited the activity of AKT phosphorylation (S473). Loss of DAB2IP, thus, promoted the phosphorylation of p27 on Serine 10 (S10) by AKT. Phosphorylated p27 was then sequestrated in cytosol, and subsequently ubiquitinated for degradation. Introduction of a constitutively activated AKT which was not affect by DAB2IP ablated the effect of DAB2IP on RCC growth, while introduction of a mutated p27 (p27 S10A) which escaped from the phosphorylation of AKT significantly restored the suppressive role of DAB2IP. In RCC patients, DAB2IP negatively correlated with tumor size and positively correlated with p27 expression. Survival analysis indicated that DAB2IP was associated with a better overall survival of RCC patient.
CONCLUSIONS: This study identifies DAB2IP as a tumor suppressor in RCC, and its mechanism of action is to stabilize p27 via suppressing PI3K/AKT signaling.
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MP60-02 IRON DEPRIVATION DOWNREGULATES HIF2-a AND INDUCES CANCER-SPECIFIC APOPTOSIS IN CLEAR CELL RENAL CELL CARCINOMA
Christopher Greene*, Nitika Sharma, Gary Smith, Kenneth Gross, Eric Kauffman, Buffalo, NY INTRODUCTION AND OBJECTIVES: The von Hippel Lindau (VHL)/hypoxia inducible factor-alpha (HIF-a) pathway is commonly dysregulated in clear cell renal cell carcinoma (ccRCC) and potentially exacerbated by oxidative stress. Ferric iron is the most abundant heavy metal in the human body and is required for nephrogenesis in utero; it is also a major source of intracellular oxidative stress capable of inducing ccRCC tumorigenesis in rodent models. In addition to its known requirement for DNA synthesis, iron was recently shown to stabilize HIF2-a transcript by inhibiting iron regulatory protein 1. Still, a role for iron in human ccRCC tumorigenesis remains largely unexplored. Here we test the hypotheses that intracellular iron levels are increased in ccRCC cells and that iron reduction can effectively reduce HIF2-a expression and suppress ccRCC cell growth.
METHODS: Iron levels were measured in 100 RCC patient tumors using Prussian Blue stain and compared to levels in benign renal tubule epithelium. Protein levels of the main iron uptake protein, transferrin receptor 1 (TfR1/CD71), were compared between 4 VHLdeficient ccRCC cell lines and 2 benign renal epithelial cell lines by flow cytometry and western blot. Micromolar concentrations of 3 clinically approved iron chelator drugs, deferoxamine (DFO), deferiprone (DFP), and deferisirox (DFX) were tested by MTT assay for effects on ccRCC versus benign renal cell proliferation. Cell viability and apoptosis induction with DFO treatment was measured in select ccRCC cell lines using flow cytometry analysis of annexin-V and 7-AAD stains, as were effects of DFO on ccRCC HIF2-a protein levels.
RESULTS: Increased intracellular iron was detected in ccRCC tumors compared to benign renal tubule epithelium. All ccRCC cell lines had elevated TfR1 expression compared to benign renal cell lines. Iron chelation treatment using DFO, DFP, or DFX achieved 80-90% growth reduction in all ccRCC cell lines at clinically relevant concentrations, while benign renal cell lines were relatively resistant. The mechanism underlying ccRCC growth inhibition included cell death via apoptosis, whereas benign renal cells had no increased death even after prolonged iron chelation treatment. Intriguingly, iron chelation in ccRCC cell lines effectively downregulated HIF2-a in a time-and concentrationdependent manner.
CONCLUSIONS: These data indicate that intracellular increases in iron content occur during human ccRCC tumorigenesis and support iron chelation as a potential therapeutic strategy for targeting HIF2-a and inducing cancer cell death in ccRCC patients.
